Back to results
US 2014/0271685 A1Published application
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
AssigneeThe Regents of the University of California
InventorBIN LIU
Life of this patent
Estimating the term…
Abstract
In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).
Claims31
An isolated antibody that specifically binds and is internalized into a prostate cancer cell, wherein:
- said antibody is an antibody that specifically binds cells that express or overexpress a CD46, wherein said antibody specifically binds sushi domain 1 of said CD46;
- and
- said antibody does not comprise VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the following antibodies:
- 3051.1, G12FC3, M6c42b, 4F3YW, M40pr146, UA20, UA8, 585II41, 585II41.1, 585II56, 3076, 3051, M49R, RCI-14, II79—4, II79—3, T5II-4B.1, T5II-4B.2, RCI-11, RCI-20, CI-11A, CI-14A, S95-2, and mPA7.
1 more element
(canceled)
9-10. (canceled)
15-16. (canceled)
(canceled)
20-21. (canceled)
25-40. (canceled)
42-43. (canceled)
45-68. (canceled)
70-76. (canceled)
Dependencies are inferred from the claim text.